Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals
- PMID: 24347474
- PMCID: PMC4277819
- DOI: 10.1002/jlcr.3165
Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals
Abstract
The development of chelating agents for copper radionuclides in positron emission tomography radiopharmaceuticals has been a highly active and important area of study in recent years. The rapid evolution of chelators has resulted in highly specific copper chelators that can be readily conjugated to biomolecules and efficiently radiolabeled to form stable complexes in vivo. Chelators are not only designed for conjugation to monovalent biomolecules but also for incorporation into multivalent targeting ligands such as theranostic nanoparticles. These advancements have strengthened the role of copper radionuclides in the fields of nuclear medicine and molecular imaging. This review emphasizes developments of new copper chelators that have most greatly advanced the field of copper-based radiopharmaceuticals over the past 5 years.
Keywords: PET; chelator; copper 64; molecular imaging; radiopharmaceutical.
© 2013 The Authors. J. Label Compd. Radiopharm published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no conflicts of interest.
Figures






Similar articles
-
Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).Acc Chem Res. 2009 Jul 21;42(7):832-41. doi: 10.1021/ar800255q. Acc Chem Res. 2009. PMID: 19530674 Free PMC article.
-
Copper radionuclides and radiopharmaceuticals in nuclear medicine.Nucl Med Biol. 1996 Nov;23(8):957-80. doi: 10.1016/s0969-8051(96)00130-8. Nucl Med Biol. 1996. PMID: 9004284 Review.
-
Copper chelation chemistry and its role in copper radiopharmaceuticals.Curr Pharm Des. 2007;13(1):3-16. doi: 10.2174/138161207779313768. Curr Pharm Des. 2007. PMID: 17266585 Review.
-
Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis.Dalton Trans. 2022 Mar 29;51(13):5041-5052. doi: 10.1039/d2dt00209d. Dalton Trans. 2022. PMID: 35285835 Free PMC article.
-
Novel hexadentate and pentadentate chelators for ⁶⁴Cu-based targeted PET imaging.Bioorg Med Chem. 2014 Apr 15;22(8):2553-62. doi: 10.1016/j.bmc.2014.02.041. Epub 2014 Mar 1. Bioorg Med Chem. 2014. PMID: 24657050 Free PMC article.
Cited by
-
Methods for the Production of Radiolabeled Bioagents for ImmunoPET.Methods Mol Biol. 2024;2729:117-142. doi: 10.1007/978-1-0716-3499-8_8. Methods Mol Biol. 2024. PMID: 38006494 Free PMC article. Review.
-
Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.Cancers (Basel). 2022 Apr 14;14(8):1996. doi: 10.3390/cancers14081996. Cancers (Basel). 2022. PMID: 35454902 Free PMC article.
-
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.Theranostics. 2020 Jan 1;10(1):437-461. doi: 10.7150/thno.38366. eCollection 2020. Theranostics. 2020. PMID: 31903131 Free PMC article. Review.
-
Peptide-based fibrin-targeting probes for thrombus imaging.Dalton Trans. 2017 Oct 31;46(42):14488-14508. doi: 10.1039/c7dt02634j. Dalton Trans. 2017. PMID: 29051933 Free PMC article. Review.
-
Pilot Study of 64Cu(I) for PET Imaging of Melanoma.Sci Rep. 2017 May 31;7(1):2574. doi: 10.1038/s41598-017-02691-3. Sci Rep. 2017. PMID: 28566692 Free PMC article.
References
-
- James ML, Gambhir SS. Physiol Rev. 2012;92:897. - PubMed
-
- Gillings N. Magn Reson Mater Phys, Biol Med. 2013;26:149.
-
- Bartholomä MD. Inorg Chim Acta. 2012;389:36.
-
- Coles MP. Annu Rep Prog Chem, Sect A: Inorg Chem. 2012;108:220.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous